Core Viewpoint - The establishment of three major biopharmaceutical projects in Chengdu High-tech Zone signifies a strategic move to enhance the local biopharmaceutical ecosystem, focusing on high-tech and critical areas such as biobreeding, high-end medical devices, and cell therapy [1][2]. Group 1: Project Details - The three signed projects include a comprehensive medical device service platform and CDMO project by Beijing Shuimu Medical, a biobreeding and intelligent equipment pilot platform by Hancheng Guangyi, and a high-end cell therapy culture medium production headquarters and R&D base by Shengji Saier [1][2]. - Shuimu Medical aims to create a one-stop service system covering engineering design, testing, clinical trials, registration, and contract development and manufacturing (CDMO) [1]. Group 2: Competitive Advantages - Chengdu possesses significant advantages for developing the medical device industry, including quality educational resources, strong research capabilities, abundant medical resources, and a mature IT industry foundation [2]. - The local detection support is crucial for medical device R&D, and the new projects are expected to enhance the local innovation ecosystem and shorten the R&D and market launch cycles for innovative medical devices [2]. Group 3: Financial Initiatives - Chengdu has launched a "Chain Master Fund Action Plan," aiming to establish 12 chain master funds by the end of 2030, with a total scale exceeding 60 billion yuan, to drive emerging industries and improve resource allocation [2]. - The introduction of the chain master fund is anticipated to attract more leading enterprises to Chengdu, further enhancing the development of the biopharmaceutical industry chain [2]. Group 4: Industry Ecosystem - Chengdu High-tech Zone has been recognized as a leading biopharmaceutical hub, ranking just behind Zhongguancun and Suzhou Industrial Park in terms of comprehensive competitiveness [3]. - The "Wutong Plan" launched by Chengdu High-tech Zone aims to provide a full lifecycle service list for the biopharmaceutical industry, covering 47 service directions and 99 detailed services [3]. Group 5: Future Development - Chengdu High-tech Zone plans to continue fostering an open and innovative environment, integrating global resources to enhance the biopharmaceutical industry's development [4]. - The focus will be on breaking through key technologies and cultivating world-class industrial clusters to establish a globally influential biopharmaceutical innovation source and industrial hub [4].

重磅签约：三大项目锚定前沿，锻造产业关键链条 在本次交流会的签约环节，成都生物医药产业迎来重大发展机遇。现场集中签约9个生物医药产业链重大项目，其中3个项目落户成都高新区。 本次成都高新区签约的三大项目均具备高技术含量与强链补链的战略意义，精准落子成都高新区生物医药产业发展的关键环节。 6月19日，2025"投资成都"全球招商大会生物医药产业园区发展交流会在成都天府国际生物城举行，吸引了来自国家部委、地方政府、产业园区、知名企 业、金融机构及智库机构的150余位嘉宾齐聚一堂，共话生物医药产业园区的高质量发展之路。 会上，水木医疗创新医疗器械全产业链服务平台及CDMO项目、瀚辰光翼生物育种及智能装备中试平台项目、生基赛尔高端细胞治疗类培养基生产总部及产 研基地项目集中签约落户成都高新区，涉及生物育种、高端医疗器械、细胞治疗等关键前沿领域，为成都打造具有全球竞争力的生物医药产业生态注入澎湃 动能。 本次活动还设主题报告、投资推介、行业分享等环节，全面展示成都生物医药产业的创新活力与投资潜力。 国家纳米科学中心研究员赵宇亮在题为《纳米医药与药物递送纳米技术》的主题报告中，深入剖析了纳米技术对医药产业的颠覆性影响。 ...